Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Holders of 5% or more of CADL
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Candel Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%6.32M shares | +5.70 ppfrom 9.30% | Feb 9, 20224 filings | Feb 7, 2025 | SEC |
| RTW Investments, LP | 13G | 8.80%6.42M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Manning Paul B | 13D/A | 7.90%5.79M shares | – | Feb 14, 20222 filings | Mar 18, 2026 | SEC |
| BlackRock, Inc. | 13G | 6.60%4.83M shares | +2.40 ppfrom 4.20% | Jan 21, 20263 filings | Jul 27, 2026 | SEC |
| Acorn Bioventures, L.P. | 13G | 5.20%2.58M shares | New | Jun 30, 20251 filing | Jun 30, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
16 Schedule 13D and 13G filings on Candel Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jul 27, 20264:25 PM ET | BlackRock, Inc. | 13G | 6.60%4.83M shares | +2.40 ppfrom 4.20% | Jun 30, 2026 | SEC |
| May 15, 20268:08 AM ET | RTW Investments, LPand 1 other | 13G | 8.80%6.42M shares | New | Mar 31, 2026 | SEC |
| Apr 27, 20264:12 PM ET | BlackRock, Inc. | 13G/A | 4.20%3.08M shares | −1.00 ppfrom 5.20%Below 5% | Mar 31, 2026 | SEC |
| Mar 18, 20264:23 PM ET | Manning Paul Band 2 others | 13D/A | 7.90%5.79M shares | – | Dec 16, 2024 | SEC |
| Jan 21, 202612:30 PM ET | BlackRock, Inc. | 13G | 5.20%2.86M shares | New | Dec 31, 2025 | SEC |
| Jun 30, 20259:55 AM ET | Acorn Bioventures, L.P.and 4 others | 13G | 5.20%2.58M shares | New | Jun 25, 2025 | SEC |
| May 15, 20254:33 PM ET | Baker Bros. Advisors LPand 3 others | 13G/A | 4.99%2.46M shares | −1.81 ppfrom 6.80%Below 5% | Mar 31, 2025 | SEC |
| Feb 14, 20255:32 PM ET | Northpond Ventures, LPand 4 others | 13G/A | 0.00%0 shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 20254:14 PM ET | Baker Bros. Advisors LPand 3 others | 13G | 6.80%2.98M shares | New | Dec 31, 2024 | SEC |
| Feb 7, 20254:09 PM ET | CVI Investments, Inc.and 1 other | 13G/A | 0.00%0 shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 7, 202510:18 AM ET | FMR LLCand 1 other | 13G/A | 15.00%6.32M shares | +5.70 ppfrom 9.30% | Jan 31, 2025 | SEC |
| Feb 7, 202510:03 AM ET | FMR LLCand 1 other | 13G | 9.30%3.92M shares | – | Dec 31, 2024 | SEC |
| Feb 9, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Manning Paul B | 13DOld format | – | New | – | SEC |
| Feb 14, 2022 | Northpond Ventures, LP | 13GOld format | – | New | – | SEC |
| Feb 9, 2022 | FMR LLC | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Candel Therapeutics, Inc. shares.
No Form 144 notices for Candel Therapeutics, Inc. are on file.